Metastatic Uveal Melanoma Clinical Trial
— HAITILSOfficial title:
A Phase I Study Using Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases
The purpose of this study is to evaluate the feasibility, safety and tolerability of treatment with autologous tumor infiltrating lymphocytes (TIL) administered via hepatic arterial infusion in patients with liver metastases (including but not restricted to) of malignant melanoma.
Status | Recruiting |
Enrollment | 6 |
Est. completion date | February 2030 |
Est. primary completion date | February 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Patients 18-75 years of age on the day of signing informed consent. 2. Patient is willing and able to provide written informed consent and comply with study procedures. Written informed consent must be signed and dated before the start of specific protocol procedures. 3. Patient must have a histologically/cytologically confirmed diagnosis of: - stage IV uveal melanoma with or without any previous systemic therapy OR - stage IV cutaneous melanoma with confirmed progression following at least one or two prior systemic therapies including a programmed cell death protein-1 (PD-1) inhibitor with or without a CTLA-4 inhibitor; and if BRAF V600 mutation-positive, also a BRAF inhibitor or a BRAF inhibitor in combination with a MEK inhibitor. 4. Measurable disease by computed tomography (CT) per RECIST 1.1 criteria with at least one target lesion identified in the liver and where the distribution pattern of metastasis is predominantly engaging the liver as judged by the investigator. 5. At least one resectable lesion in the liver (or aggregate of lesions resected) of a minimum size of 0.5 cm in diameter post- resection to generate TILs. 6. ECOG performance status of 0 - 2. 7. Female patient of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. 8. Female patients of childbearing potential must be willing to use a highly efficient method of contraception (Pearl index <1), for the course of the study through 120 days after the last dose of study medication. 9. Male patients with women of childbearing potential partners must agree to use a condom for contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy. Exclusion Criteria: 1. Life expectancy of less than 3 months. 2. History of interstitial lung disease (ILD) or (non-infectious) pneumonitis. 3. Reduced renal function defined as S- Creatinine >=1.5xULN or Creatinine Clearance < 40 mL/min, calculated using the Cockroft and Gault formula. 4. Reduced hepatic function (defined as ASAT, ALAT, bilirubin > 3*ULN and PK- INR > 1.5) or medical history of liver cirrhosis or portal hypertension. 5. Hemoglobin <90 g/L or platelets <100x109/L or neutrophils <1.5x109/L 6. Use of live vaccines four weeks before or after the start of study. 7. History of severe hypersensitivity reactions to monoclonal antibodies. 8. Active infection. 9. Infection of human immunodeficiency virus (HIV), acquired immunodeficiency syndrome (AIDS), hepatitis B or hepatitis C. 10. Active autoimmune disease or a history of known or suspected autoimmune disease. 11. A condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses >10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. 12. Concomitant therapy with any other anti- cancer therapy, concurrent medical conditions requiring use of immunosuppressive medications or use of other investigational drugs. 13. Has a known additional malignancy of other diagnosis that is progressing or requires active treatment. 14. Pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study drug. 15. A history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator. |
Country | Name | City | State |
---|---|---|---|
Sweden | Department of Oncology, Sahlgrenska University Hospital | Gothenburg |
Lead Sponsor | Collaborator |
---|---|
Vastra Gotaland Region | Miltenyi Biomedicine GmbH |
Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) | Adverse events are graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 | 5 years from start of chemotherapy | |
Secondary | Objective response rate (ORR) | Defined by RECIST 1.1 | 2 years from start of chemotherapy | |
Secondary | Clinical benefit rate (CBR) | Defined by RECIST 1.1 | 18 weeks | |
Secondary | Progression free survival (PFS) | Evaluation of progression-free survival | 2 years | |
Secondary | hepatic Progression free survival (hPFS) | Evaluation of hepatic progression-free survival | 2 years | |
Secondary | Duration of objective response (DOR) | Evaluation of duration of response | 2 years | |
Secondary | Overall Survival (OS) | Evaluation of overall survival | 5 years | |
Secondary | Evaluation of feasibility of an automated production of TILs | Defined as the proportion of patients included that receive treatment with the TIL product. | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03068624 -
Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
|
Phase 1 | |
Recruiting |
NCT04728633 -
Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases
|
Phase 2 | |
Recruiting |
NCT05987332 -
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
|
Phase 2/Phase 3 | |
Completed |
NCT01551459 -
A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma
|
Phase 2 | |
Active, not recruiting |
NCT00986661 -
A Study to Assess PV-10 Chemoablation of Cancer of the Liver
|
Phase 1 | |
Completed |
NCT01585194 -
Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
|
Phase 2 | |
Withdrawn |
NCT01328106 -
Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma
|
Phase 2 | |
Recruiting |
NCT05075993 -
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT04552223 -
Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma
|
Phase 2 | |
Recruiting |
NCT05607095 -
Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Patients With Metastatic Uveal Melanoma
|
Phase 1 | |
Active, not recruiting |
NCT01587352 -
Vorinostat in Treating Patients With Metastatic Melanoma of the Eye
|
Phase 2 | |
Active, not recruiting |
NCT03025256 -
Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease
|
Phase 1 | |
Active, not recruiting |
NCT03472586 -
Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver
|
Phase 2 | |
Terminated |
NCT04879017 -
FHD-286 in Subjects With Metastatic Uveal Melanoma
|
Phase 1 | |
Terminated |
NCT01814046 -
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma
|
Phase 2 | |
Recruiting |
NCT03947385 -
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03865212 -
Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma
|
Phase 1 | |
Active, not recruiting |
NCT05022901 -
An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma
|
Phase 3 | |
Recruiting |
NCT05282901 -
Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME)
|
Phase 2 | |
Recruiting |
NCT05415072 -
A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas
|
Phase 1/Phase 2 |